Detection and Diagnostic Utilization of Cellular and Cell-Free Tumor DNA.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021(2021)

引用 18|浏览19
暂无评分
摘要
Because cancer is caused by an accumulation of genetic mutations, mutant DNA released by tumors can be used as a highly specific biomarker for cancer. Although this principle was described decades ago, the advent and falling costs of next-generation sequencing have made the use of tumor DNA as a biomarker increasingly practical. This review surveys the use of cellular and cell-free DNA for the detection of cancer, with a focus on recent technological developments and applications to solid tumors. It covers () key principles and technology enabling the highly sensitive detection of tumor DNA; () assessment of tumor DNA in plasma, including for genotyping, minimal residual disease detection, and early detection of localized cancer; () detection of tumor DNA in body cavity fluids, such as urine or cerebrospinal fluid; and () challenges posed to the use of tumor DNA as a biomarker by the phenomenon of benign clonal expansions.
更多
查看译文
关键词
benign clonal expansions,cell-free DNA,cfDNA,circulating tumor DNA,ctDNA,molecular genetic pathology,next-generation sequencing,oncology
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要